These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 28914263

  • 1. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.
    Tang Z, Zhang J, Lu X, Wang W, Chen H, Robinson MK, Cheng J, Tang G, Medeiros LJ.
    Mod Pathol; 2018 Feb; 31(2):307-312. PubMed ID: 28914263
    [Abstract] [Full Text] [Related]

  • 2. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
    Piton N, Ruminy P, Gravet C, Marchand V, Colasse É, Lamy A, Naoures Mear CL, Bibeau F, Marguet F, Guisier F, Salaün M, Thiberville L, Jardin F, Sabourin JC.
    Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734
    [Abstract] [Full Text] [Related]

  • 3. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
    Melchior L, Hirschmann A, Hofman P, Bontoux C, Concha A, Mrabet-Dahbi S, Vannuffel P, Watkin E, Putzová M, Scarpino S, Cayre A, Martin P, Stoehr R, Hartmann A.
    Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
    [Abstract] [Full Text] [Related]

  • 4. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
    Augustin J, Gabignon C, Scriva A, Menu L, Calmel C, Scatton O, Paye F, Fléjou JF, Praz F, Cervera P, Wendum D.
    Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
    [Abstract] [Full Text] [Related]

  • 5. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z, Yu X, Zhang Y.
    Cancer Biol Ther; 2017 Nov 02; 18(11):883-887. PubMed ID: 27635639
    [Abstract] [Full Text] [Related]

  • 6. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
    Lee SE, Lee B, Hong M, Song JY, Jung K, Lira ME, Mao M, Han J, Kim J, Choi YL.
    Mod Pathol; 2015 Apr 02; 28(4):468-79. PubMed ID: 25234288
    [Abstract] [Full Text] [Related]

  • 7. [Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma].
    Ma XL, Jia RN, Han K, Zhang YX.
    Zhonghua Bing Li Xue Za Zhi; 2024 Jun 08; 53(6):578-584. PubMed ID: 38825903
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K, Hida T, Oya Y, Yoshida T, Shimizu J, Mizuno T, Kuroda H, Sakakura N, Yoshimura K, Horio Y, Sakao Y, Yatabe Y.
    Cancer; 2017 May 15; 123(10):1731-1740. PubMed ID: 28177518
    [Abstract] [Full Text] [Related]

  • 10. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K, Mochizuki M, Kohno M, Shu S, Harada N, Yoshimura Y.
    BMC Cancer; 2019 Apr 03; 19(1):301. PubMed ID: 30943926
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ, Ritterhouse LL, Ali SM, Bailey M, Schrock AB, Gainor JF, Ferris LA, Mino-Kenudson M, Miller VA, Iafrate AJ, Lennerz JK, Shaw AT.
    J Thorac Oncol; 2017 May 03; 12(5):872-877. PubMed ID: 28088512
    [Abstract] [Full Text] [Related]

  • 15. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S, Zhang H, Bai D, Gao D, Zheng J, Ding Y.
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep 03; 44(9):639-43. PubMed ID: 26705279
    [Abstract] [Full Text] [Related]

  • 16. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, Li B, Cai D, Shen L, Sun Y, Chen H.
    Lung Cancer; 2014 May 03; 84(2):121-6. PubMed ID: 24629636
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
    Grosse A, Grosse C, Rechsteiner M, Soltermann A.
    Diagn Pathol; 2019 Feb 11; 14(1):18. PubMed ID: 30744664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.